Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

42 results about "Pseudotyping" patented technology

Pseudotyping is the process of producing viruses or viral vectors in combination with foreign viral envelope proteins. The result is a pseudotyped virus particle. With this method, the foreign viral envelope proteins can be used to alter host tropism or an increased/decreased stability of the virus particles. Pseudotyped particles do not carry the genetic material to produce additional viral envelope proteins, so the phenotypic changes cannot be passed on to progeny viral particles.

Production of pseudotyped recombinant AAV virions

InactiveUS7094604B2Highly purified and concentratedEfficient and large-scale productionVectorsSugar derivativesPurification methodsSerotype
Vectors that encode Adeno-Associated Virus (AAV) Rep and Cap proteins of different serotypes and Adenovirus transcription products that provide helper functions were used to produce pseudotyped recombinant AAV (rAAV) virions. Purification methods generated pseudotyped rAAV virion stocks that were 99% pure with titers of 1×1012–1×1013 vector genomes / ml.
Owner:UNIVIRSITY OF FLORIDA RES FOUND INC

Cocal vesiculovirus envelope pseudotyped retroviral vectors

Provided herein are Cocal vesiculovirus envelope pseudotyped retroviral vectors that exhibit high titers, broad species and cell-type tropism, and improved serum stability. Disclosed Cocal vesiculovirus envelope pseudotyped retroviral vectors may be suitably employed for gene therapy applications and, in particular, for the ex vivo and in vivo delivery of a gene of interest to a wide variety of target cells.
Owner:FRED HUTCHINSON CANCER RES CENT

Single-domain antibodies for novel coronavirus and application of single-domain antibodies

The invention discloses humanized single-domain antibodies for a novel coronavirus SARS-CoV-2 and an application of the humanized single-domain antibodies. The invention protects the single-domain antibodies described in any one of SEQ ID No.1 to SEQ ID No.5. Experimental results show that the single-domain antibodies provided by the invention have good affinity with receptor binding domain (RBD)antigens and have high neutralization activity on SARS-CoV-2 pseudovirus. The humanized single-domain antibodies have important scientific significance and application prospect for prevention and clinical treatment of the new coronavirus SARS-CoV-2 and for development of diagnostic reagents of the new coronavirus SARS-CoV-2.
Owner:BEIJING KAWIN TECH SHARE HLDG

Modified baculovirus expression system for production of pseudotyped rAAV vector

InactiveUS20060166363A1Reduce lossesEfficient and high productionAnimal cellsSugar derivativesBaculovirus expressionHelper virus
The invention provides modifications to a baculovirus-based recombinant adeno associated virus (AAV) system including enhancement of the helper virus stability and construction of novel baculovirus vectors for rAAV pseudotyping. The modified system extends the flexibility of rAAV vector production and promotes the utility of AAV as, a clinically applicable gene therapy vector.
Owner:UNIV OF FLORIDA RES FOUNDATION INC

Antiviral agents and vaccines against influenza

These vaccines target H5N1, H1, H3 and other subtypes of influenza and are designed to elicit neutralizing antibodies, as well as cellular immunity. The DNA vaccines express hemagglutinin (HA) or nucleoprotein (NP) proteins from influenza which are codon optimized and / or contain modifications to protease cleavage sites of HA which affect the normal function of the protein. Adenoviral constructs expressing the same inserts have been engineered for prime boost strategies. Protein-based vaccines based on protein production from insect or mammalian cells using foldon trimerization stabilization domains with or without cleavage sites to assist in purification of such proteins have been developed. Another embodiment of this invention is the work with HA pseudotyped lentiviral vectors which would be used to screen for neutralizing antibodies in patients and to screen for diagnostic and therapeutic antivirals such as monoclonal antibodies.
Owner:US DEPT OF HEALTH & HUMAN SERVICES

Pseudotyping of retroviral vectors, methods for production and use thereof for targeted gene transfer and high throughput screening

ActiveUS20100189690A1Increase in titer and transduction efficiencyHigh transduction efficiencySsRNA viruses negative-senseBiocideSurface markerMorbillivirus
The invention relates to the pseudotyping of retroviral vectors with heterologous envelope proteins derived from the Paramyxoviridae family, genus Morbillivirus, and various uses of the resulting vector particles. The present invention is based on the unexpected and surprising finding that the incorporation of morbillivirus F and H proteins having truncated cytoplasmic tails into lentiviral vector particles, and the complex interaction of these two proteins during cellular fusion, allows for a superior and more effective transduction of cells. Moreover, these pseudotyped vector particles allow the targeted gene transfer into a given cell type of interest by modifying a mutated and truncated H protein with a single-chain antibody or ligand directed against a cell surface marker of the target cell.
Owner:BUNDESREPUBLIK DEUTLAND LETZTVERTRETEN DURCH DEN PRASIDENTEN DES PAUL EHRLICH INSTITUTS

Process for preparing retrovirus vector for gene therapy

InactiveUS20010018203A1High recovery rateStably produced at a high titerVectorsGenetic material ingredientsPol genesA-DNA
The present invention provides a process for preparing a retrovirus to be expressed at a high titer by specifically transferring a desired foreign gene into target cells. A pseudotyped retrovirus vector having a high titer can be prepared by transferring a DNA construction wherein a promoter, an loxP sequence, a VSV-G gene and a polyA addition signal are arranged in this order is transferred into cells carrying the retrovirus gag and pol gene expression systems, and then transferring a retrovirus vector containing the desired foreign gene thereinto, followed by the treatment with a recombinase.
Owner:EISIA R&D MANAGEMENT CO LTD

Pseudotyped lentiviral vectors and uses thereof

A vector system that will produce a pseudotyped lentiviral vector that can be used to deliver a desired gene is disclosed. The vector constructs that are described include a number of modifications that enhance the safety of the vector. The vector can be used to more specifically target cells for expression of certain genes.
Owner:DANA FARBER CANCER INST INC

HIV medicament screening cell model and special pseudotype lentivirus therefor

The invention discloses an HIV drug screening cell model and special pseudotype slow virus thereof; the invention constructs recombinant plasmid for expressing Gag gene and Pol gene of HIV, recombinant slow-virus plasmid for expressing reporter gene and recombinant plasmid for expressing Rev gene of HIV; the three plasmids and recombinant plasmid for expressing glycoprotein gene of capsid G of herpetic stomatitis are transfected in the cells of mammals so as to obtain pseudotype slow virus; the pseudotype slow virus is used for infecting the cells of mammals, thus obtaining the HIV drug screening cell model based on the reporter gene. The HIV drug screening cell model provided by the invention uses the virus with one-time infection with good safety and the reporter gene leads the cell model to have super high sensitivity.
Owner:MICROBE EPIDEMIC DISEASE INST OF PLA MILITARY MEDICAL ACAD OF SCI

HIV stain drug-resistant phenotype analytical cell model and special pseudotype lentivirus therefor

InactiveCN101353667ARapid Phenotypic Resistance AnalysisSafety Phenotypic Resistance AnalysisMicrobiological testing/measurementViruses/bacteriophagesPhenotypic resistanceReverse transcriptase
The invention discloses a cell model of HIV strain phenotypic drug resistance analysis and special pseudotype slow virus thereof; the invention constructs plasmid for expressing Gag protein of HIV, recombinant slow-virus plasmid for expressing reporter gene and helper plasmid for expressing Rev protein of HIV; under the effect of the helper plasmid pVSV-G, the three plasmid and HIV reverse transcriptase and the gene fragment of protease which are amplified from strain can obtain the pseudotype slow virus of the HIV reverse transcriptase and protease gene containing strain. The pseudotype slow virus is used for infecting the cells of mammals, thus obtaining the strain phenotypic resistance cell model based on the reporter gene. The cell model of the invention can carry out phenotypic resistance analysis to the strain, the reporter gene leads the cell model to have super high sensitivity, and the cell model of HIV strain phenotypic drug resistance analysis is applicable to the phenotypic drug resistance analysis of HIV strain in Chinese population.
Owner:MICROBE EPIDEMIC DISEASE INST OF PLA MILITARY MEDICAL ACAD OF SCI

Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof

The present disclosure provides methods and compositions for genetically modifying lymphocytes and related methods that include genetically modifying T cells and / or NK cells. The methods use replication incompetent recombinant retroviral particles that comprise a pseudotyping element on their surface and optionally a membrane-bound T cell activation element, such as an anti-CD3, and encode one ormore engineered signaling polypeptides that can include a lymphoproliferative element, and / or a chimeric antigen receptor (CAR). The methods can include contacting PBMCs with replication incompetent recombinant retroviral particles for various exemplary time periods, such as less than 24 hours or in some illustrative embodiments less than 15 minutes. Illustrative chimeric lymphoproliferative elements that are capable of promoting survival and / or proliferation of T cells or NK cells in culture without adding IL-2, are provided. Furthermore, additional regulatory elements are provided, such as inhibitory RNA molecules.
Owner:埃克苏马生物技术公司

Human DPP4 gene knock-in mouse model and production method and use thereof

The present invention provides a human DPP4 gene knock-in mouse model and a production method and use thereof. Specifically, human DPP4 is accurately inserted into a safe harbor locus of a mouse genome without changing mouse DPP4 function to establish a novel homozygous mouse model in which a human DPP4 gene is knocked into the mouse safe harbor locus. The invention also provides the use of the mouse model in which the human DPP4 gene is knocked into the genome in infection of a mouse with a low dose MERS-CoV euvirus in a BSL-3 facility and evaluation of the in-vivo efficacy of anti-MERS-CoV antiviral agents and vaccines or infection of the mouse with pseudotype MERS-CoV virus in a biological laboratory lacking the BSL-3 facility and evaluation of the in-vivo efficacy of the anti-MERS-CoVantiviral agents and vaccines.
Owner:NAT INST FOR FOOD & DRUG CONTROL

Pseudo MERS-CoV virus of infected animal, and preparation method and application thereof

The invention relates to a pseudo MERS-CoV virus packaging system, a method for preparing pseudo MERS-CoV viruses by in-vitro transfection of cells using the pseudo MERS-CoV virus packaging system, and a mouse model with knock-in of a hDPP4 (human dipeptidyl peptidase 4) gene infected by the pseudo MERS-CoV viruses in a biological laboratory lack of BSL-3 (biological safety level 3), so as to evaluate the in-vivo effects of an anti-virus agent and a vaccine.
Owner:NAT INST FOR FOOD & DRUG CONTROL

Methods for selectively modulating the activity of distinct subtypes of cells

The present invention relates to pseudotyped retrovirus-like particles or retroviral vectors comprising both engineered envelope glycoproteins derived from a virus of the Paramyxoviridae family fusedto a cell targeting domain and fused to a functional domain. The present invention also relates to the use of said pseudotyped retrovirus-like particles or retroviral vectors to selectively modulate the activity of specific subsets of cells, in particular of specific immune cells. These pseudotyped retrovirus-like particles or retroviral vectors are particularly useful for gene therapy, immune therapy and / or vaccination.
Owner:ECOLE NORMALE SUPERIEURE DE LYON +3

Method for specifically knocking out fumarylacetoacetate hydrolase (FAH) gene by using CRISPR-Cas9 and specific sgRNA

PendingCN111100876AKnockout fastKnockout precisionHydrolasesStable introduction of DNABiotechnologyLentivirus
The invention relates to a method for specifically knocking out a fumarylacetoacetate hydrolase (FAH) gene by using CRISPR-Cas9 and specific sgRNA. The method is applied to specifically knock out theFAH gene of pigs and rabbits and comprises the following specific steps: S1: selection and design of a sgRNA target sequence; S2: construction of a CRISPR-Cas9 vector of the FAH gene; S3: obtaining ofa pseudotype lentivirus expressing FAH sgRNA and Cas9 protein; and S4: infection of a target cell and detection of an FAH gene knockout effect. The target sequence of the specific sgRNA on the FAH genes of the pigs and rabbits conforms to a sequence arrangement law of 5'-N(20)NGG-3'. The specific sgRNA is applied to the method for specifically knocking out the FAH gene of the pigs and rabbits byusing the CRISPR-Cas9, can rapidly, accurately, efficiently and specifically knock out the FAH gene of the pigs and rabbits respectively, and effectively solves the technical problems of long period and high cost in construction of pigs and rabbits with the FAH gene knocked out.
Owner:立沃生物科技(深圳)有限公司

Method for nk cell transduction

The present invention discloses an in-vitro method for transferring biological material into activated NK cells with a pseudotyped retroviral vector particle or a virus-like particle thereof, comprising the steps a) activation of NK cells, and b) addition of said pseudotyped retroviral vector particle or virus-like particle thereof to said activated NK cells, wherein said pseudotyped retroviral vector particle or virus-like particle thereof comprises a modified baboon endogenous retrovirus (BaEV) envelope glycoprotein that is able of binding to and fusing with a hematopoietic cell membrane, thereby transferring biological material into said activated NK cells. Preferentially, the activating of NK cells is performed by the addition of a IL-1 family cytokine to the NK cells.
Owner:MILTENYI BIOTEC B V & CO KG

Engineered Exosomes for the Delivery of Bioactive Cargo Using Transmembrane VSV-G

Vesicular stomatitis virus glycoprotein (VSVG) can both load protein cargo onto exosomes and increase their delivery ability via a pseudotyping mechanism. By fusing a set of fluorescent and luminescent reporters with VSVG, we show the successful targeting and incorporation of VSVG fusions into exosomes by gene transfection and fluorescence tracking. VSVG pseudotyping of exosomes does not affect the size or distributions of the exosomes, and both the full-length VSVG and the VSVG without the ectodomain integrate into the exosomal membrane, suggesting that the ectodomain is not required for protein loading. Finally, exosomes pseudotyped with full-length VSVG are internalized by multiple-recipient cell types to a greater degree compared to exosomes loaded with VSVG without the ectodomain, confirming a role of the ectodomain in cell tropism. This invention provides a new genetically encoded pseudotyping platform to load and enhance the intracellular delivery of therapeutic proteins via exosome-based vehicles to target cells.
Owner:SANTA CLARA UNIVERSITY

Pseudotype insect baculovirus gene transfer system for prawns, virus, construction method and application

The invention relates to a pseudotype insect baculovirus gene transfer system for prawns, a virus, a construction method and an application, and belongs to the technical field of genetic engineering.The pseudotype insect baculovirus gene transfer system for prawns disclosed by the invention comprises a Bac-to-Bac insect baculovirus expression system, prawn virus envelope protein gene expression plasmids and insect packaging cells. The pseudotype insect baculovirus gene transfer system for prawns disclosed by the invention can stably and efficiently transfer and express exogenous genes in prawn tissue and cells.
Owner:OCEAN UNIV OF CHINA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products